News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
63 Results
Type
Article (1)
Press Release (62)
Section
Business (31)
Career Advice (1)
Deals (10)
Drug Development (9)
Job Trends (2)
News (43)
Policy (2)
Tag
Alliances (3)
Best Places to Work (1)
Career advice (1)
Clinical research (3)
Earnings (15)
Events (1)
Healthcare (3)
IPO (9)
Job creations (1)
Job search strategy (1)
Mergers & acquisitions (1)
NextGen: Class of 2025 (2)
People (11)
Phase I (1)
Phase II (1)
Postmarket research (1)
Preclinical (6)
Regulatory (2)
Date
2022 (2)
2021 (4)
2020 (7)
2019 (7)
2018 (12)
2017 (12)
2016 (2)
2015 (5)
2014 (3)
2011 (2)
Location
Africa (1)
Asia (3)
Australia (2)
Europe (1)
South America (1)
63 Results for "cardax".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardax Refocuses on ZanthoSyn® Consumer Health Business
Cardax, Inc., announced today that it is refocusing its business strategy on its astaxanthin dietary supplement ZanthoSyn® for consumer health.
August 31, 2021
·
5 min read
Business
Cardax Reports 2020 Results
Cardax, Inc. (OTCQB:CDXI) reported its 2020 results
April 15, 2021
·
6 min read
Policy
Cardax Voluntarily Suspends SEC Reporting Obligations
Cardax, Inc. announced the filing of a Form 15 with the U.S. Securities and Exchange Commission to voluntarily suspend its reporting obligations under Section 15 of the Securities Exchange Act of 1934.
August 11, 2021
·
3 min read
Business
Cardax Reports Q2 2020 Results
Cardax, Inc. (OTCQB:CDXI) reported its Q2 2020 results
August 14, 2020
·
6 min read
Business
Cardax Reports Q3 2019 Results
Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019.
November 14, 2019
·
5 min read
Business
Cardax Reports Q2 2019 Results
Cardax, Inc. filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.
August 14, 2019
·
5 min read
Cardax, Inc. Announces Reverse Stock Split of Common Stock
Cardax expects that upon the opening of trading on January 15, 2020, its common stock will trade on the OTCQB on a split-adjusted basis under the current symbol “CDXI” and the new CUSIP number 14141D201.
January 14, 2020
·
4 min read
Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease
Cardax seeking strategic collaborations to further develop astaxanthin for COVID-19 (OTCQB:CDXI) today released a white paper outlining the potential role of astaxanthin in the treatment of coronavirus disease and is seeking strategic collaborations to further develop astaxanthin for COVID-19. The
March 20, 2020
·
7 min read
Business
Cardax Reports 2018 Results
Cardax, Inc. announced results for the year ended December 31, 2018, in its Annual Report on Form 10-K filed today with the SEC.
March 28, 2019
·
6 min read
Cardax Announces Interim Results from CHASE Clinical Trial
Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE (Cardiovascular Health Astaxanthin Supplement Evaluation) clinical trial.
September 23, 2019
·
6 min read
1 of 7
Next
